Gynecomastia on Spironolactone: Eplerenone or Finerenone for Bilateral Aldosteronism
A single patient whose bilateral disease rules out surgery, left choosing among three real mineralocorticoid receptor antagonists after the first-line option became intolerable.
Martin O., a 57-year-old high school baseball coach, has bilateral adrenal hyperplasia confirmed as the source of his primary aldosteronism on adrenal vein sampling — bilateral disease that rules out the surgical cure a unilateral adenoma would offer, leaving lifelong mineralocorticoid receptor antagonism as his actual treatment. He coached the same varsity team for eighteen years and jokes, not entirely joking, that pacing a dugout in July heat is its own stress test his blood pressure has never quite passed. Spironolactone controlled his blood pressure well at 50 mg daily, but six weeks in he developed real, painful bilateral gynecomastia, a known antiandrogenic effect of the drug's off-target progesterone and androgen receptor activity, and has told his team plainly that he'd rather have uncontrolled blood pressure than go through that again. His actual choice now sits between two real alternatives with genuinely different maturity of evidence behind them.
Eplerenone, a more selective steroidal antagonist without spironolactone's antiandrogenic baggage, has decades of use and FDA approval specifically for hypertension, though the comparative literature has consistently found it less potent at blood-pressure lowering than spironolactone at comparable doses. Finerenone, a genuinely different, nonsteroidal antagonist, is FDA-approved only for chronic kidney disease with type 2 diabetes and for heart failure, not for primary aldosteronism specifically — any use here would be off-label. Finerenone's approvals rest on FIDELIO-DKD and FIGARO-DKD in chronic kidney disease with type 2 diabetes and on FINEARTS-HF in heart failure; there is no trial of that stature in primary aldosteronism at all. What exists is a handful of small, recent open-label series suggesting it is comparably effective to spironolactone at lowering blood pressure in primary aldosteronism with a more favorable hyperkalemia and antiandrogenic profile, but these are small, early trials measured against spironolactone's decades of established outcomes data, not the other way around.
Endocrinology follow-up, after spironolactone intolerance
Eplerenone is FDA-approved for hypertension specifically, has decades of real-world use, and doesn't carry the progesterone and androgen receptor cross-reactivity that caused his gynecomastia. Given what he just went through, I'd try the established, better-characterized option next rather than something newer.
I'd actually go straight to finerenone. Small recent series in primary aldosteronism specifically — his actual diagnosis, not just hypertension generally — have found it comparably effective to spironolactone at lowering blood pressure, with a better hyperkalemia and antiandrogenic profile. Eplerenone's real, documented weakness is lower potency at comparable doses, and I'd rather not risk another round of inadequate control before trying the option with evidence closer to his specific condition.
I take the maturity-of-evidence point seriously — finerenone's data here is genuinely newer and smaller — but "newer" isn't the same as "less relevant" when it's the evidence that actually matches his diagnosis.
I'd sequence rather than choose outright. Eplerenone's weakness — lower potency — is quick to find out and easy to escalate from if it isn't enough. Start there, recheck his blood pressure in four to six weeks, and move to finerenone specifically if eplerenone under-controls him, rather than starting with the less mature, harder-to-access, off-label option before we know the better- established one has actually failed him.
Agreed: start eplerenone with blood pressure and potassium reassessed in four to six weeks, and move to finerenone specifically if eplerenone doesn't achieve adequate control.
Not agreed: how much of a blood pressure shortfall should count as "inadequate" and trigger the switch. The endocrinologist would move to finerenone at any meaningful shortfall from goal, given the disease-specific evidence behind it; the primary care physician would want a higher bar before abandoning an on-label, well-established drug for an off-label one.